Sandbox/Alejandro: Difference between revisions
< Sandbox
Line 236: | Line 236: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |▸ '''''[[Azithromycin]] 500 mg PO q24h''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left |PLUS |
Revision as of 15:57, 6 June 2014
Neutropenic Patients
- Patients with neutropenia require an antimicrobial therapy with a broader coverage.
- The duration of antimicrobial therapy should be individualized in accordance with patient's clinical response.
Microorganism | Duration of Therapy |
▸ Gram-negative Bacteria | 7-14 days |
▸ Gram-positive Bacteria | 7-10 days |
▸ Fungi | Until clinical resolution |
▸ Click on the following categories to expand treatment regimens.
Neutropenia ▸ Gram-Negative Bacteria ▸ Gram-Positive Bacteria ▸ Fungi
|
|
Cellular Immune Deficient Patients
- Patients with cellular immunodeficiency require a pathogen-specific antimicrobial therapy.
- The duration of antimicrobial therapy should be individualized in accordance with patient's clinical response.
Microorganism | Duration of Therapy |
▸ Nocardia spp | 3-12 months |
▸ Atypical mycobacteria | 3-6 weeks |
▸ Cryptococcus spp | 8-12 weeks |
▸ Histoplasma spp | ≥ 12 months |
▸ Varicella-zoster virus | 7-10 days |
▸ Herpes simplex virus | 7 days |
▸ Cytomegalovirus | 21 days |
Bacteria ▸ Nocardia spp ▸ Atypical mycobacteria Fungi ▸ Cryptococcus spp ▸ Histoplasma spp Viruses ▸ Varicella-zoster virus ▸ Herpes simplex virus ▸ Cytomegalovirus |
|
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin (2007). "An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X.
- ↑ Wheat, LJ.; Freifeld, AG.; Kleiman, MB.; Baddley, JW.; McKinsey, DS.; Loyd, JE.; Kauffman, CA. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045. Unknown parameter
|month=
ignored (help)